Over the last six years, several manuscripts have focused on the effects of PI3K/Akt/mTOR signaling activation in hematopoietic stem cells (HSCs) with regard to the development of malignant hematopoietic disorders, including acute leukemias. The gene discussed is MTOR; the disease is acute leukemia.